Glial cell line-derived neurotrophic factor (GDNF) holds great promise for the treatment of Parkinson's disease. In humans, its intracerebroventricular administration leads to limiting side effects. Direct parenchymal delivery using mechanical means, or cell and gene therapy represent potential alternatives. In the present study, a representative of each of these three approaches, i.e. polymer rods, genetically modified encapsulated cells and lentiviral vectors was analyzed for its ability to release GDNF in the striatum of rats. One week post-surgery, GDNF was detected over a distance of 4 mm with all three methods. At 4 weeks GDNF staining diminished with rods and to a lesser extent with encapsulated cells, whereas it increased with lentiviral vectors. Nanogram range of GDNF was measured with all methods at 1 week. At 4 weeks, GDNF levels decreased significantly with rods, whereas they remained stable with encapsulated cells and lentiviral vectors. We conclude that all three methods investigated allow striatal delivery of GDNF, but the time during which it needs to be released will determine the approach chosen for clinical application. 
diseases, such as nerve growth factor (NGF) for Buchs, Switzerland) was sieved to a size ,37 mm Alzheimer's disease (AD), glial cell line-derived using scrynel PET33HC meshes (PolyLabo). A 10% neurotrophic factor (GDNF) for Parkinson's disease (w / v) solution of purified EVA in methylene chloride (PD), or ciliary neurotrophic factor (CNTF) for solvent was prepared with 23% BSA (w / w total) and Huntington's disease (HD) [1, 2] . Several clinical 1% recombinant human GDNF (Amgen) (w / w trials have been conducted with each of these factors, total), vortexed and sonicated until reaching a so far, however, without success. Part of the probhomogenous solution. The solution was then quickly lems may be related to inefficient delivery technique.
frozen and placed into a lyophilizer for 48-72 h until The CNS delivery of NTFs is limited by factors the solvent was completely evaporated. The mixture such as (i) their inability to cross the blood-brainwas pressure extruded at 55 8C through a cylindrical barrier, (ii) their poor stability in a fluid environdiameter die, and 10-cm-long rods were kept at 4 8C ment, (iii) their limited diffusion through brain in a dessicator until use. Before implantation, 5-mm parenchyma, and (iv) the side-effects associated with rods were cut and sterilized by immersion in 0.1 N binding to extra-target receptors [3, 4] . Intracerebhydrochloric acid for 1 min, 70% ethanol for 1 min, roventricular (ICV) administration eliminates the and sterile PBS for 2 min. need to bypass the blood-brain-barrier. Poor diffusion within the brain parenchyma [5, 6] and occur-2 .2. Characterization of the C C -GDNF cell line 2 12 rence of severe side-effects limit, however, its applicability. Excruciating pain was indeed described The pCI-neo expression vector (Promega, with the ICV administration of NGF in AD patients
Madison, WI, USA) was modified as previously [7, 8] ; weight loss, nausea and abnormal sexual described [11] . The fragment containing the mutated behavior was reported with the ICV administration of dihydrofolate reductase gene (DHFR) under the GDNF in PD patients [9] . In contrast, animal expericontrol of the SV40 promoter and the hepatitis virus ments have shown that direct parenchymal adminis-B 39 untranslated region (HBV-39 UTR) was obtration dramatically reduces the occurrence of sidetained from the RP3224D plasmid [12] digested with effects reported with ICV application [5, 10] . These PvuII. The isolated fragment was subcloned into the observations emphasize the need for localized, suspCI-Neo vector digested with BamHI and blunted, tained delivery of these molecules in specific nuclei using the T4 polymerase to fill in the protruding of the CNS.
ends. The resulting vector pCI-ND was digested with Direct localized CNS delivery is achievable either BglII and EcoRI to remove the cytomegalovirus by mechanical means, or by cell or gene therapy. In (CMV) promoter. The murine phosphoglycerate the context of this work, we have chosen to compare kinase 1 promoter and a chimeric intron excised a representative of each of the three approaches for from the pCI-PGK-GIP-R / IRES / GLP-1 vector [13] the intrastriatal delivery of GDNF, a promising via BglII /EcoRI digestion, was subcloned into the trophic factor for the treatment of PD, and deduct the BglII /EcoRI site of the pCI-ND plasmid, forming relative advantages / disadvantages of the three delivthe pPI-DN vector. Rockville, MD, USA), transfected by calcium phosby ultracentrifugation, and tested for the absence of phate precipitation (Mammalian transfection kit, replication-competent viral vectors. The GDNF-exStratagene, La Jolla, CA, USA) with the pPI-DNTpressing viral stocks were matched for viral particle hGDNF plasmid, were selected with 0.8 mg / ml content (|110,000 ng p24 antigen / ml as measured 8 G418 for 2 weeks, and the integrated plasmid was by ELISA assay) corresponding to |3-7310 TU / then amplified with increasing concentrations of ml. methotrexate (1 to 200 mM) over 4 weeks. Stability of transgene expression was achieved by alternating 2 .5. Animals cell incubation weekly in media containing either 0.8 mg / ml G418 or 200 mM methotrexate for an addiAdult female Wistar rats (Iffa-Credo, France), tional 6 weeks. The C C engineered cells were weighing 180-200 g were used in these studies. 2 12 then maintained in culture media supplemented with They were housed in a controlled temperature room 0.8 mg / ml G418. Twenty-five clones isolated by that was maintained in a 12 h light / dark cycle. Food limiting dilution were tested for GDNF secretion by and water were available ad libitum. The experi-ELISA assay (R&D Systems, Abingdon, UK) as ments were carried out in accordance with the well as for their differentiation and survival propEuropean Community Council directive (86 / 609 / erties in hollow fibers. The clone [19 producing EEC) for care and use of laboratory animals. 10% fetal calf serum, 1% penicillin / streptomycin, group were then unilaterally implanted into the and 2 mM L-glutamine (Life Technologies, Paisley, striatum with 5-mm-long GDNF-releasing polymer Scotland, UK). After dissociation, cells were susrods (0.5 mm anterior to bregma, 3 mm lateral to the pended at a density of 25,000 cells / ml culture midline, and 7 mm ventral from the dura), or with medium. Six microliters (150,000 cells) of the cell 5-mm-long C C -GDNF capsules (0.5 mm anterior, 2 12 solution were injected into 500-mm inner diameter 3 mm lateral, 7.5 mm ventral), or were injected with poly(ether-sulfone) (PES) fibers (5 mm long; AKZO-2 ml of concentrated lenti-GDNF (0.5 mm anterior, 3 Fiber Nobel, Wupperthal, Germany) previously filled mm lateral, 5 mm ventral) at the speed of |0.2 with a poly(vinyl) alcohol (PVA) cylindrical matrix ml / min. (Rippey Corporation, CA, USA). The ends of the One week and 4 weeks post surgery, nine animals fibers were sealed with a polymerized acrylic-based were sacrificed with an overdose of pentobarbital. glue (Ablestic Laboratories, NJ, USA) and kept in Three were perfused transcardially with ice-cold culture medium at 37 8C and 5% carbon dioxide phosphate buffer saline (PBS) containing 0.02% before transplantation.
ascorbic acid, their brains were removed and fresh tissue punches (2.832 mm) in the striatum including 2 .4. GDNF-expressing lentiviral vectors the injection site were rapidly collected and kept at 280 8C before processing for hGDNF ELISA assay. The generation of viral particles was performed
The remaining six animals were perfused with PBS / with a four-plasmid system as previously described ascorbic acid and with 4% paraformaldehyde. The [14] . Briefly, the cDNAs encoding the human GDNF brains were post-fixed in a solution of 4% paraforcontaining a Kozak consensus sequence were cloned maldehyde for 24 h and then placed in 25% sucrose for an additional 24 h. They were then frozen on dry polymer rods or hollow fibers, and the injection of ice and 25 mm coronal sections were cryocut lentiviral vectors into the rat striatum, immunothroughout the entire striatum and stored at 4 8C in histochemical detection of hGDNF was performed to PBS containing 0.12 mM sodium azide.
characterize the diffusion of the NTF throughout this structure (Fig. 1) . One week post-surgery, GDNF 2 .7. hGDNF ELISA assay staining was present over a maximal distance of 4 mm in the three groups, which almost corresponds to Brain punches on the ipsi-and contralateral side the entire striatum volume according to the rat brain (n53 per condition) were collected and processed to atlas of Paxinos and Watson [16] (Fig. 1A-C) . Line measure the amount of hGDNF using an ELISA source (polymer rods and encapsulated cells), as well assay (Promega) as previously described [15] .
as multiple point source (lentiviral vectors) delivery techniques, show a similar pattern of GDNF staining.
.8. Immunohistochemical detection of hGDNF
GDNF detection was restricted to the striatum as delineated by the corpus callosum. In order to evaluate the diffusion of GDNF in the Four weeks post-surgery, GDNF staining was striatum, immunohistochemistry using biotinylated detected over |2 mm throughout the striatum in the goat anti-human GDNF antibodies (R&D Systems, case of polymer rods (Fig. 1D ), 3 mm with the Abingdon, UK; 1:250) was performed on 25-mmthick cryosections as previously described [14] .
.9. Image analysis
Diffusion of hGDNF was determined by digitizing 18 hGDNF-stained sections per animal (250 mm between each section) throughout the entire striatum with a slide scanner and quantifying the optical density with an image analysis public domain program (NIH-Image, Version 1.6.1, National Institutes of Health, USA). Data are expressed as optical density, corresponding to the sum of gray values of all the pixels in the selection. The contralateral side was used to determine the background density. The corpus callosum and the anterior commissure were used as hallmarks to delimit the striatal area.
.10. Statistical analysis
Data were analyzed for significance (set at P, 0.05) using analysis of variance (ANOVA) followed by a Scheffe's PLSD post-hoc test (JMP 3.0, SAS Institute, USA). encapsulated cells (Fig. 1E) , and over 4 mm with volume. Interestingly, the ratio of the GDNF imlentiviral vectors (Fig. 1F) (Fig. 3) . However, at 4 weeks post-surgery, the three methods were statistically In order to quantify and compare the diffusion different from the 1 week time point with a decrease pattern of GDNF in the striatum using the three in this ratio for the rods (5.262.8%) and the delivery methods, optical density of GDNF immunocapsules (18.265.8%), and an increase for the histochemical staining was measured throughout the lentivirus group (72.864.5%). Similar results were entire striatum using the NIH image analysis proobtained in cubic millimeters and compared to the gram (Fig. 2) . One week post-surgery, optical denestimated striatal volume ( (Fig. 4) .
. Results

staining in the striatum
At 4 weeks post-surgery, the amount of GDNF released by the polymer rods dramatically decreased Using the same image analysis program, the (0.460.003 ng GDNF / mg protein), whereas capvolume of GDNF immunohistochemical staining was sules and lentiviral vectors showed sustained and measured and compared to the ipsilateral striatal similar levels of GDNF around the injection site (1.760.3 and 1.760.05 ng GDNF / mg protein, relocalized expression of significant amounts of GDNF spectively). At either 1 or 4 weeks post-surgery, in the striatum. Although the diffusion pattern of contralateral values were similar to naive animals GDNF was approximately identical with the three (,0.15 ng GDNF / mg protein), except for the lenapproaches at 1 week post-surgery, results of the tiviral vectors, where small amounts of GDNF were 4-week time point suggest that polymer rods are detected at the 4-week time point (0.560.3 ng suitable for localized short-term protocols, whereas GDNF / mg protein). The amounts of GDNF mealentiviral vectors and encapsulated cells are more sured by ELISA assay represent maximum values in adapted methods for long-term applications. localized punches around the injection site and not Several studies have reported encouraging results absolute values within the entire striatum, thus using polymer rods releasing NTFs. Following a explaining the discrepancies observed between Figs. fimbria-fornix lesion, NGF released from EVA / BSA 3 and 4 at the 4-week time point between capsules rods in the ipsilateral ventricle for 2 weeks prevented and lentiviral vectors.
the loss of choline acetyltransferase expression in the medial septum and vertical diagonal band region [17] . More recently, Tornqvist et al. have demon-4 . Discussion strated that polymer rods secreting NTFs such as epidermal growth factor, basic fibroblast growth In the present study, we have compared the factor and GDNF can enhance fetal dopaminergic efficiency of three different methods for delivery of graft survival, outgrowth, and functions, when cothe neurotrophic factor GDNF in the brain parenimplanted with a striatal fetal graft in a rat model of chyma of adult rats. Polymer rods, encapsulated cells PD [18] . Consistent with our results, they found that and lentiviral vectors enable the continuous and polymer rods allowed the local secretion of the NTFs for |2 weeks. Conceptually, polymer rods could be applied in a clinical setting especially as they are retrievable provided adequate geometry. Their use will, however, be limited to applications necessitating only short term delivery. As of today, EVA is also not approved for clinical use. Several studies have shown the ability of encapsulated cells releasing NTFs to provide neuroprotection and neuroregeneration both in rodent [19] [20] [21] [22] [23] and primate [24, 25] models of neurodegenerative disorders. Scale-up in the human has already been achieved through a phase I clinical trial using sclerosis patients [26, 27] . The device was well tolerated and did not lead to significant side-effects.
ly, a system allowing the regulation of transgene Viable and functional encapsulated cells were still expression in the advent of limiting side-effects. observed 17 weeks post-implantation. One of the Encouraging preliminary results have already been most promising applications of NTFs consists in the obtained with lentiviral vectors encoding various co-implantation of fetal mesencephalic cells with transgenes under the tetracycline-inducing system encapsulated cells releasing GDNF [20] . GDNF [32, 33] . indeed increases the number of surviving dopaminergic neurons as well as enhancing the neurite outgrowth from these cells. Besides chronic delivery, 5 . Conclusion the encapsulation technique also allows the treatment to be arrested in case of appearance of limiting
The present work reveals the efficiency of three side-effects as capsules are retrievable by a simple different delivery methods in providing a significant surgical procedure.
amount of GDNF in the rat striatum. These data The present study reveals the ability of lentiviral open interesting perspectives for the treatment of vectors to lead to sustained delivery of GDNF in the neurodegenerative diseases. The dose and the time rat striatum. GDNF staining was detected over a during which GDNF needs to be administered, i.e. greater volume 4 weeks post-injection compared to 1 more detailed pharmacokinetics for the administraweek. This observation is probably related to the tion of this trophic factor in the CNS will require long half-life of GDNF within the brain parenchyma.
further investigations to determine which one of Previous experiments have reported long-term exthese approaches would be particularly relevant in a pression of the transgene up to 1 year in rodents [28] given clinical indication for the targeted neurodeand 8 months in primates [15] . Long-term stable generative disease. transgene expression is most probably related to the integration of the viral genome into the host chromosome [29] . Surprisingly, some GDNF was also A cknowledgements detected in the contralateral striatum, as a result of chronic diffusion of the neurotrophic factor from
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